RNAConnect, Inc. Formally Launches Today to Drive RNA Analysis With Innovative Research Tools

BRANFORD, CO / ACCESSWIRE / May 23, 2024 / RNAConnect, a pioneering life science reagent company, officially launches today, promising groundbreaking solutions for exploring the real-world diversity of RNA sequence and structure.

RNAConnect was founded by innovators in the RNA community, for innovators in the RNA community. The company believes that better enzymatic tools for visualizing and manipulating RNA enable the scientific community to discover, create, and innovate in ways previously not possible.

Founded by Anna Marie Pyle, Ph.D., Yale University Professor and Howard Hughes Medical Institute Investigator, RNAConnect exclusively licensed pioneering enzymatic technology from Yale. This technology, developed in her lab, reveals the full spectrum of RNA processing and chemical modification isoforms of transcripts in cellular mixtures.

The company's co-founders include Ryan Muldoon, CEO and former CEO of PrEP Biopharm, Ltd., and a team of academic experts. Supported by Connecticut Innovations and an NIH SBIR grant, RNAConnect is set to launch its first RNA analysis products featuring the UltraMarathon Reverse Transcriptase.

"The launch of RNAConnect marks a significant milestone in the reagent industry, introducing solutions that will reshape RNA research," says Ryan Muldoon, CEO of RNAConnect.